Top

Published in:

01-08-2013 | Research Article

Is breast cancer in young Asian women more aggressive than in Caucasians? A cross-sectional analysis

Authors: Muy-Kheng M. Tea, Lei Fan, James W. Delancey, Christine Staudigl, Stefan Steurer, Christina Lang, Zhi-Ming Shao, Christian F. Singer

Published in: Tumor Biology | Issue 4/2013

Abstract

Ethnic differences in breast cancer are well described in studies comparing Hispanic and African-American populations to Caucasian populations. The aim of this study was to analyze the biological characteristics of breast cancer (BC) in the young Asian/Han Chinese population compared to Caucasians/Central Europeans. Histopathologies of 642 invasive BC in women at the age of 40 years and younger were analyzed in China and Austria. Pearson’s chi-squared test was used to assess differences in the analyzed populations. Significantly larger BC >2 cm (p < 0.0001) and poorly differentiated BC (p = 0.02) as well as more triple-negative BC (p = 0.002) were identified among the Han Chinese group compared to the Central European group. This analysis will provide ethnic-specific insight into the biological characteristics of BC in young patients worldwide.

Leong SP, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is breast cancer the same disease in Asian and Western countries? World J Surg. 2010;34(10):2308–24.PubMedCrossRef

Porter P. “Westernizing” women's risks? Breast cancer in lower-income countries. N Engl J Med. 2008;358(3):213–6.PubMedCrossRef

Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, et al. Breast cancer in a transitional society over 18 years: trends and present status in Shanghai, China. Breast Cancer Res Treat. 2009;117(2):409–16.PubMedCrossRef

Hankey BF, Miller B, Curtis R, Kosary C. Trends in breast cancer in younger women in contrast to older women. J Natl Cancer Inst Monogr. 1994;16:7–14.PubMed

Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol. 2009;36(3):237–49.PubMedCrossRef

Calle EE, Martin LM, Thun MJ, Miracle HL, Heath Jr CW. Family history, age, and risk of fatal breast cancer. Am J Epidemiol. 1993;138(9):675–81.PubMed

Lee CG, McCormick B, Mazumdar M, Vetto J, Borgen PI. Infiltrating breast carcinoma in patients age 30 years and younger: long term outcome for life, relapse, and second primary tumors. Int J Radiat Oncol Biol Phys. 1992;23(5):969–75.PubMedCrossRef

Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer. 1996;74(11):1796–800.PubMedCrossRef

Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol. 2008;26(20):3324–30.PubMedCrossRef

10.

Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer. 2001;92(10):2523–8.PubMedCrossRef

11.

Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999–2004. Cancer. 2008;112(4):737–47.PubMedCrossRef

12.

Yang H, Wang SY, Ou W, Sun HB, Fang Q. Clinical characteristics and prognosis of very young patients with breast cancer in the southern of China. Chin J Cancer. 2009;28(12):1310–6.CrossRef

13.

Agarwal G, Pradeep PV, Aggarwal V, Yip CH, Cheung PS. Spectrum of breast cancer in Asian women. World J Surg. 2007;31(5):1031–40.PubMedCrossRef

14.

Gajdos C, Tartter PI, Bleiweiss IJ. Lymphatic invasion, tumor size, and age are independent predictors of axillary lymph node metastases in women with T1 breast cancers. Ann Surg. 1999;230(5):692–6.PubMedCrossRef

15.

Koscielny S, Arriagada R, Adolfsson J, Fornander T, Bergh J. Impact of tumour size on axillary involvement and distant dissemination in breast cancer. Br J Cancer. 2009;101(6):902–7.PubMedCrossRef

16.

Comen EA, Norton L, Massague J. Breast cancer tumor size, nodal status, and prognosis: biology trumps anatomy. J Clin Oncol. 2011;29(19):2610–2.PubMedCrossRef

17.

Gao JD, Wang J, Feng XL, Zhong YX. Wang X: [Characterization of hormone receptor status in 5758 Chinese females with breast cancer]. Zhonghua Zhong Liu Za Zhi. 2009;31(9):683–6.PubMed

18.

Chow LW, Ho P. Hormonal receptor determination of 1,052 Chinese breast cancers. J Surg Oncol. 2000;75(3):172–5.PubMedCrossRef

19.

Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–45.PubMedCrossRef

20.

Telli ML, Chang ET, Kurian AW, Keegan TH, McClure LA, Lichtensztajn D, et al. Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry. Breast Cancer Res Treat. 2011;127(2):471–8.PubMedCrossRef

21.

Cheng HT, Huang T, Wang W, Yue JQ, Shen N, Guo H, et al. Clinicopathological features of breast cancer with different molecular subtypes in Chinese women. J Huazhong Univ Sci Technol Med Sci. 2013;33(1):117–21.PubMedCrossRef

22.

Liu JJ, Zhang S, Hao X, Xie J, Zhao J, Wang J, et al. Breast-conserving therapy versus modified radical mastectomy: Socioeconomic status determines who receives what-Results from case-control study in Tianjin, China. Cancer Epidemiol. 2012;36(1):89–93.PubMedCrossRef

Title: Is breast cancer in young Asian women more aggressive than in Caucasians? A cross-sectional analysis
Authors: Muy-Kheng M. Tea
Lei Fan
James W. Delancey
Christine Staudigl
Stefan Steurer
Christina Lang
Zhi-Ming Shao
Christian F. Singer
Publication date: 01-08-2013
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 4/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-0786-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

RETRACTED ARTICLE: XRCC3 T241M polymorphism is associated risk of hepatocellular carcinoma in the Chinese

RETRACTED ARTICLE: Associations of three common polymorphisms in CD95 and CD95L promoter regions with gastric cancer risk

RETRACTED ARTICLE: CYP2D6 T188C variant is associated with lung cancer risk in the Chinese population

Altered expression of β-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma

Effects of Rab27a on proliferation, invasion, and anti-apoptosis in human glioma cell

CYP3A5*3 polymorphism and cancer risk: a meta-analysis and meta-regression

Keynote webinar | Spotlight on antibody–drug conjugates in cancer